Evidence map›Paper›PMID 41312988›Full record

Trial reportInfection and immunity2026

A retrospectively registered pilot randomized controlled trial of postbiotic administration during antibiotic treatment increases microbiome diversity and enriches health-associated taxa.

Jonas Schluter, William Jogia, Fanny Matheis, Wataru Ebina, Alexis P Sullivan, Kelly Gordon, Elbert Fanega de la Cruz, Mary E Victory-Hays, Mary Joan Heinly, Catherine S Diefenbach and 5 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Infection and immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Jonas SchluterInstitute for Systems Genetics, New York University Grossman School of Medicine, New York, New York, USA.ORCID 0000-0002-6214-9367
William JogiaInstitute for Systems Genetics, New York University Grossman School of Medicine, New York, New York, USA.ORCID 0009-0000-5513-2375
Fanny MatheisInstitute for Systems Genetics, New York University Grossman School of Medicine, New York, New York, USA.ORCID 0000-0001-9971-3315
Wataru EbinaInstitute for Systems Genetics, New York University Grossman School of Medicine, New York, New York, USA.ORCID 0000-0001-8195-7485
Alexis P SullivanInstitute for Systems Genetics, New York University Grossman School of Medicine, New York, New York, USA.ORCID 0000-0001-9296-8112
Kelly GordonPostbiotics Plus Research, Houston, Texas, USA.
Elbert Fanega de la CruzPatients Emergency Room & Hospital, Baytown, Texas, USA.
Mary E Victory-HaysPatients Emergency Room & Hospital, Baytown, Texas, USA.
Mary Joan HeinlyPatients Emergency Room & Hospital, Baytown, Texas, USA.
Catherine S DiefenbachLaura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine, New York, New York, USA.ORCID 0000-0003-1116-3246
Un Jung KangDepartment of Neurology, New York University School of Medicine, New York, New York, USA.ORCID 0000-0002-5970-6839
Jonathan U PeledPostbiotics Plus Research, Houston, Texas, USA.ORCID 0000-0002-4029-7625
Kevin R FosterPostbiotics Plus Research, Houston, Texas, USA.ORCID 0000-0003-4687-6633
Aubrey LevittPostbiotics Plus Research, Houston, Texas, USA.
Eric McLaughlinPostbiotics Plus Research, Houston, Texas, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI FRANCESCA M GANY · 1985 to 2026
$347.4M
A prospective evaluation of the gut microbiome as a mediator of lymphoma treatment outcome and systemic immunityR01CA269617 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Catherine Sibyl Diefenbach · 2022 to 2026
$3.5M
The unleashed microbiome of cancer patients as a discovery platform for rational microbiome engineeringDP2AI164318 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SCHLUTER, JONAS · 2021 to 2025
$2.5M
Microbiota mechanisms and biomarkers in GVHDK08HL143189 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI PELED, JONATHAN · 2019 to 2023
$858k
Helen Hay Whitney FellowshipNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA269617NHLBI NIH HHS K08 HL143189NIAID NIH HHS DP2 AI164318NIH HHS DP2 AI164318-01NIH HHS K08HL143189NIH HHS R01CA269617
6 · The paper itself

Abstract

Antibiotic-induced microbiome injury, defined as a reduction of ecological diversity and obligate anaerobe taxa, is associated with negative health outcomes in hospitalized patients, and healthy individuals who received antibiotics in the past are at higher risk for autoimmune diseases. Postbiotics contain mixtures of bacterial fermentation metabolites and bacterial cell wall components that have the potential to modulate microbial communities. Yet, it is unknown if a fermentation-derived postbiotic can reduce antibiotic-induced microbiome injury. Here, we present the results from a single-center, randomized placebo-controlled trial involving 32 patients who received an oral, fermentation-derived postbiotic alongside oral antibiotic and probiotic therapy for non-gastrointestinal (GI) infections. At the end of the antibiotic course, patients receiving the postbiotic (

Indexed as

Anti-Bacterial AgentsGastrointestinal MicrobiomeMicrobiotaProbioticsAdultAgedBacteriaFecesFemaleHumansMaleMiddle AgedPilot ProjectsRetrospective StudiesAnti-Bacterial Agentsmicrobiome injurypostbiotic

Identifiers

PMID41312988
PMCPMC12797998

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.